Xinting Wang
Shuguang, 201203, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Current Perspectives on the NF-κB Signaling Axis as a Potential Pharmacological Target in Cardiorenal Syndrome.
Journal: Drug design, development and therapy
Published: August 10, 2025
Qifu yixin prescription ameliorates cardiac fibrosis by activating soluble guanylate cyclase (sGC) in heart failure.
Journal: Journal of ethnopharmacology
Published: September 21, 2024
LuQi formula ameliorates pressure overload-induced heart failure by regulating macrophages and regulatory T cells.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: September 02, 2024
Investigating the Mechanism of Chinese Medicine Formula AACO Against Chronic Heart Failure by Network Pharmacology Analysis and Experimental Validation.
Journal: Alternative therapies in health and medicine
Published: March 02, 2024
Qifu Yixin Formula Improves Heart Failure by Enhancing β-Arrestin2 Mediated the SUMOylation of SERCA2a.
Journal: Drug design, development and therapy
Published: November 13, 2023
LuQi formula attenuates Cardiomyocyte ferroptosis via activating Nrf2/GPX4 signaling axis in heart failure.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: September 21, 2023
Targeting regulatory T cells for cardiovascular diseases.
Journal: Frontiers in immunology
Published: December 18, 2022
Extracellular vesicles mediate biological information delivery: A double-edged sword in cardiac remodeling after myocardial infarction.
Journal: Frontiers in pharmacology
Published: October 12, 2022
Ginsenoside Rd Promotes Cardiac Repair After Myocardial Infarction by Modulating Monocytes/Macrophages Subsets Conversion.
Journal: Drug design, development and therapy
Published: June 07, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026